Seven Eight Capital, LP Global Blood Therapeutics, Inc. Transaction History

Seven Eight Capital, LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 04, 2022	BUY	$22.3 - $37.39 $198,313 - $332,509	8,893 New	8,893 $284,000
Q4 2021 Feb 14, 2022	SELL	$24.9 - $40.26 $830,116 - $1.34 Million	-33,338 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$25.48 - $37.34 $849,452 - $1.24 Million	33,338 New	33,338 $849,000
Q2 2021 Aug 13, 2021	SELL	$32.46 - $43.42 $938,223 - $1.26 Million	-28,904 Closed	0 $0
Q4 2020 Feb 09, 2021	SELL	$37.65 - $63.77 $246,193 - $416,992	-6,539 Reduced 18.45%	28,904 $1.25 Million
Q3 2020 Nov 16, 2020	BUY	$52.76 - $74.49 $1.65 Million - $2.33 Million	31,243 Added 743.88%	35,443 $1.95 Million
Q2 2020 Aug 06, 2020	BUY	$48.73 - $81.82 $204,666 - $343,644	4,200 New	4,200 $265,000

288K

Ticker GBT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 67,476,200
Market Cap $4.62B
Description
Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses...

Get notified when there are updates to the investment portfolio of Seven Eight Capital, LP, based on Form 13F filings with the SEC.

Stay updated on Seven Eight Capital, LP with notifications on news.